Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2013 Jun 26;273(2):10.1016/j.taap.2013.06.013. doi: 10.1016/j.taap.2013.06.013

Fig. 3.

Fig. 3

Levels of cancer relevant gene expression in CCT-LC or control cells. (A) Quantitative expression of tumor suppressor gene proteins SLC38A3 and p16. (B) Expression of the oncoproteins KRAS and NRAS. (C) Expression of the EMT marker Vimentin in CCT-LC cells. Inset: Cell morphology at 20 weeks, Bar, 50 μM. (D) Immunostaining of Vimentin, Bar, 50 μM. A p ≤0.05 was considered significant. An asterisk (*) indicates significance from control.